"" New Director Appointed Amid Financial Headwinds
Cocrystal Pharma, Inc. (NASDAQ:COCP) has appointed Carol L. Brosgart to its board of directors, effective immediately as of August 12, 2026. The company's market capitalization stands at $20.8 million, and faces financial headwinds, according to InvestingPro analysis, which suggests the company appears overvalued at its current price of $1.08.
Independent Director with No Conflicts
The appointment comes as the biotech company undergoes significant changes. Brosgart has no family relationships with Cocrystal Pharma's directors or executive officers, and there are no related party transactions involving her that require disclosure under Item 404(a) of Regulation S-K.
Leadership Changes Underway
In recent news, Cocrystal Pharma has announced the appointment of James Sapirstein as its new Chief Executive Officer, effective immediately. Sapirstein takes over from Sam Lee and Jim Martin, who served as Co-Chief Executive Officers. Lee will transition to the role of Chief Scientific Officer, while Martin will continue as Chief Financial Officer.
Sapirstein's Compensation Package
Sapirstein's compensation package includes an initial annual base salary of $265,000, with eligibility for an annual performance bonus of up to 50% of his salary, based on performance targets. These developments mark a significant shift in Cocrystal Pharma's leadership structure.
About Cocrystal Pharma
Cocrystal Pharma is incorporated in Delaware and its common stock is listed on the Nasdaq Capital Market under the symbol COCP.